Partial dopamine agonist therapy of levodopa-induced dyskinesias.
We administered the partial dopamine agonist terguride under controlled conditions to patients with Parkinson's disease (PD), both as monotherapy and in conjunction with intravenous levodopa. Terguride produced a dose-dependent decrease in levodopa-induced dyskinesias (up to 53%) in seven patients without concomitant worsening of parkinsonism, and had no significant antiparkinsonian effect when administered alone. Partial dopamine agonists may hold some promise in the adjuvant therapy of patients with advanced PD.
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.
F
F
Baronti
M M
MM
Mouradian
K E
KE
Conant
M
M
Giuffra
G
G
Brughitta
T N
TN
Chase
D000328:Adult; D000368:Aged; D015259:Dopamine Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008090:Lisuride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D009068:Movement
D015259:Dopamine Agents; C006208:dironyl; D007980:Levodopa; D008090:Lisuride